BioBusiness

This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Having remote operations in place is crucial to maintaining good automation practices.

Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable?

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

NIH trial shows remdesivir accelerates recovery; Gilead study shows similar efficacy for 5- and 10-day dosing.

Experts to discuss strategies for ensuring supply of quality drug products during a pandemic in April 28 online event.

Successful negotiation of life-sciences collaboration agreements involves careful planning.

The company closed two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, for a total of $1.46 billion combined.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes and relocating some facilities that had been offshore.

As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.

Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.

Research from data and analytics company GlobalData shows that CAR-T cell therapy innovations across APAC will make the global market for these therapies more competitive.

As patent disputes within the scientific community continue, drug developers consider the intellectual property unknowns associated with this emerging technology.

Emergency actions to protect patients and the drug supply may have long-term implications.

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes, and relocating some facilities that had been offshore.

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.